Targeted silencing of MLL5β inhibits tumor growth and promotes gamma-irradiation sensitization in HPV16/18-associated cervical cancers

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2572-2582

  Nin, Dawn Sijin ^a   Yew, Chow Wenn ^a   Tay, Sun Kuie ^b   Deng, Lih Wen ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ISOPROTEIN; MIXED LINEAGE LEUKEMIA 5 BETA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MLL5 PROTEIN, HUMAN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SIZE; CELL AGING; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; FEMALE; GAMMA IRRADIATION; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PROTEIN TARGETING; RADIATION INJURY; RADIOSENSITIZATION; SENESCENCE; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; RADIATION RESPONSE; RANDOMIZATION; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MICE; MICE, INBRED BALB C; RANDOM ALLOCATION; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919477584     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0019     Document Type: Article

References (41)

1. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
2. World Health Organization. Fact sheet No. 297: cancer; 2006. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/index.html.
3. Bosch F, Lorincz A, Munoz N, Meijer C, Shah K. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
4. de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11.
5. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24 Suppl 3:S3/26-34.
6. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 1995;92:1654-8.
7. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21.
8. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer science 2007;98:1505-11.
9. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;61:1129-36.
10. Scheffner M, Huibregtse JM, Vierstra PD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
11. Talis AL, Huibregtse JM, Howley PM. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 1998;273:6439-45.
12. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001;20:7888-98.
13. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991;88:5523-7.
14. Barbosa M, Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989;4:1529-32.
15. Woodworth CD, Doniger J, DiPaolo JA. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J Virol 1989;63:159-64.
16. Kalantari M, Blennow E, Hagmar B, Johansson B. Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas. Diagn Mol Pathol 2001;10:46-54.
17. Tidy J, Vousden KH, Mason P, Farrell PJ. A novel deletion within the upstream regulatory region of episomal human papillomavirus type 16. J Gen Virol 1989;70:999-104.
18. Romanczuk H, Villa LL, Schlegel R, Howley PM. The viral transcriptional regulatory region upstream of the E6 and E7 genes is a major determinant of the differential immortalization activities of human papillomavirus types 16 and 18. J Virol 1991;65:2739-44.
19. Schneider-Gadicke A, Schwarz E. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J 1986;5:2285-92.
20. Smotkin D, Wettstein F. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sci USA 1986;83:4680-4.
21. Lea JS, Lin KY. Cervical cancer. Obstet Gynecol Clin North Am 2012;39:233-53.
22. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
23. Huang H, Huang SY, Chen TT, Chen JC, Chiou CL, Huang TM. Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells. J Cell Biochem 2004;91:756-65.
24. Wesierska-Gadek J, Schloffer D, Kotala V, Horky M. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer 2002;101:128-36.
25. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20.
26. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003;22:5938-45.
27. Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 2005;68:1311-9.
28. Chen J, Xie J. Progress on RNAi-based molecular medicines. Int J Nanomed 2012;7:3971-80.
29. Gu W, Payne E, Sun S, Burgess M, McMillan NA. Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs. Cancer Gene Ther 2011;18:219-27.
30. Zhou J, Peng C, Li B, Wang F, Zhou C, Hong D, et al. Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Gynecol Oncol 2012;124:296-302.
31. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21:6041-8.
32. Tan TMC, Ting RCY. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res 1995;55:4590-605.
33. Yew CW, Lee P, Chan WK, Lim VKJ, Tay SK, Tan TMC, et al. A novel MLL5 isoform that is essential to activate E6 and E7 transcription in HPV16/18-associated cervical cancers. Cancer Res 2011;71:6696-707.
34. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987;7:2745-52.
35. Psyrri A, DeFilippis RA, Edwards APB, Yates KE, Manuelidis L, DiMaio D. Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells. Cancer Res 2004;64:3079-86.
36. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009;61:746-59.
37. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31:1869-83.
38. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 2012;64:706-21.
39. Davidson BL, McCray PB Jr. Current prospects for RNA interferencebased therapies. Nat Rev Genet 2011;12:329-40.
40. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013;3:406-17.
41. Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WGV, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000;157:1055-62.